M528101

M528101 is a novel small molecule Janus kinase (JAK) inhibitor developed by Maruho Co., Ltd. for the topical treatment of atopic dermatitis and eczema. By inhibiting the JAK-STAT signaling pathway, M528101 aims to modulate the production and signaling of pro-inflammatory cytokines that are central to the pathogenesis of skin inflammation and pruritus. The compound has been evaluated in Phase I clinical trials in the Netherlands, where its safety, tolerability, and pharmacokinetics were assessed in both healthy volunteers and patients with atopic dermatitis. As a topical agent, it is designed to provide localized anti-inflammatory effects while minimizing systemic exposure and associated side effects.